eGenesis, Inc.

eGenesis, Inc. , based in the US, is a biotechnology firm specializing in genetic engineering to create Human Compatible (HuCo™) organs and cells for transplantation, aiming to alleviate organ shortages and enhance patient outcomes. Founded in 2015 and headquartered in Cambridge, US, eGenesis, Inc. focuses on developing xenotransplantation solutions.

The company has completed 6 deals, with its most recent being a Series D funding round on September 4, 2024, raising USD 191 mn led by Lux Capital. The firm was co-founded by George Church, a notable figure in genetics, and is currently led by CEO Julie Sunderland and co-CEO Michael Curtis. eGenesis is a biotechnology company focused on revolutionizing organ and cell transplantation through its innovative multiplex gene editing and genome engineering platform. The company's flagship offerings include the development of Human Compatible (HuCo™) organs and cells, particularly targeting xenotransplantation solutions for kidney and islet cells.

These products aim to address the critical shortage of transplantable organs, improving patient outcomes and extending quality of life for individuals with serious organ failures. eGenesis's technologies leverage the latest advancements in gene editing to create organs compatible with human biology, expanding the potential donor pool and reducing wait times for traditional organ transplants. The company primarily serves healthcare providers, transplant centers, and research institutions in the US, with aspirations to extend into international markets facing similar organ shortages. eGenesis generates revenue through strategic partnerships and collaborations within the healthcare industry, focusing on B2B transactions with healthcare providers and research institutions.

The company’s revenue model involves licensing agreements and collaborative research funding to support the development and commercialization of its HuCo™ organ and cell products. Transactions include upfront fees for licensing its proprietary technologies, followed by milestone payments as specific research and development goals are achieved, fostering long-term relationships within the healthcare ecosystem. In September 2024, eGenesis, Inc. raised USD 191 mn in Series D funding led by Lux Capital, with participation from Khosla Ventures, ARCH Venture Partners, and others.

This funding will be utilized to advance a clinical trial for transplanting its genetically modified pig kidney, scale production, and pursue additional pipeline programs. The company aims to expand its market presence by targeting international regions experiencing severe organ shortages, although specific markets and timelines for this expansion have yet to be detailed.